国产喹硫平与氯氮平治疗精神分裂症的疗效比较

目的 :探讨喹硫平治疗精神分裂症的疗效及不良反应。方法 :6 0例精神分裂症病人分为 2组 ,喹硫平组 30例 ,男性 19例 ,女性 11例 ,年龄 (37±s8)a ,给予喹硫平 ,氯氮平组 30例 ,男性 2 0例 ,女性10例 ,年龄 (36± 8)a ,给予氯氮平 ,2组开始剂量约为 5 0mg·d- 1,以后视病情调整 ,分别为 (42 3± 2 0 )mg·d- 1和 (415± 18)mg·d- 1,分 2次口服 ,共治疗 6wk ,采用阳性症状与阴性症状量表 (PANSS)评定临床疗效 ,同时用不良反应症状量表 (TESS)评定不良反应。结果 :喹硫平组的有效率达 87% ,与氯氮平组 (6 0 % )比较无显著差异 (P >0 .0 5 )。喹硫平组的不良反应中活动减少、视物模糊、便秘、流涎、头晕、体重增加的发生率显著少于氯氮平组 (P <0 .0 1或P <0 .0 5 )。结论 :国产喹硫平治疗精神分裂症的疗效是肯定的 ,与氯氮平相似 ,不良反应轻、少 ,是一种安全、有效的抗精神病药

Effects of domestic quetiapine vs clo-zapine in treatment of schizophrenia

AIM:To probe the efficacy and adverse reactions of quetiapine in the treatment of schezophrenia. METHODS:Sixty patients were randomly divided into 2 groups. Quetiapine group of 30 patients (M 19, F 11; age (37± s 8)a) and clozapine group 30 patients (M 20, F 10; age (36±8)a) were treated with quetiapine (50 mg·d -1 at first, then adjusted to (423±20)mg·d -1 according to the degree of illness) and clozapine (50 mg·d -1 at first, then adjusted to (415±18)mg·d -1 according to the degree of illness) for 6 wk, respectively. Positive and negative symptom scale(PANSS) was used to assess clinical efficacy and treatment emergent symptom scale (TESS) was used to assess adverse reactions. RESULTS: The effective rate of quetiapine group was 87 %, almost the same as clozapine group (60 %) .The adverse reactions of quetiapine group; such as hypoactivity, blurred vision, constipation, sialorrhea, dizziness and increase of body weight were less than those of clozapine group( P <0.01 or P <0.05 ). CONCLUSION: In the treatment of schezophrenia,the effect of domestic quetiapine is the same as that of clozapine and the adverse reactions are less than those of clozapine. Quetiapine is a kind of safe and effective antipsychotic.